Interferon Interest Zooms; NCI Awarding Production Contracts, Proceeds With Plans For Clinical Trials
In Brief: NIH Reviewers, Advisors To Get Increase In Honoraria; Price Leaving NCI for Maryland
Recision, 1981 Budget Threats Hangover NCI
Frelick Heads ACCC, Kerman Names President-Elect
CCIRC Told Group Radiation Studies Cost $20,000 Per 25 Patients
Skipper To Receive Bristol-Myers Award
Pathology Review Confirms Reserpine As Carcinogen
Trending Stories
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures - In weekly vigils, current and former NIH staff grieve the impact of Trump cuts
The Saturday gatherings at NIH’s Metro station are part graveside service, part street theater - She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research
- Scaling excellence: How City of Hope is transforming cancer care delivery
- First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI